First Clinical Studies with Orlistat: A Short Review

Abstract

Lipase inhibition, leading to decreased intestinal fat adbsorption can be used in the treatment of obesity. Orlistat, a lipase inhibitor, in a dose of 50 mg three times a day leads to a significant increase in weight loss compared to placebo in moderately obese people. These results are confirmed in a multiple‐dose study using 10 mg, 60 mg and 120 mg Orlistat three times a day vs. placebo. The use of lipase inhibition has no significant influence on fasting levels of several hormonal systems, including thyroid hormones, catecholamines and IGF‐I. The same is true for the responses of several gastrointestinal and pancreatic hormones after a liquid high‐fat mixed meal. In general, Orlistat is tolerated very well, although a higher occurence of gastrointestinal side effects is seen.